natgillin/translations-raw huggingface dataset:
Patients hypersensitive to Insuman Basal for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insuman Basal, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insuman Comb 15 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insuman Comb 15, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insuman Comb 25 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insuman Comb 25, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insuman Comb 30 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insuman Comb 30, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insuman Comb 50 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insuman Comb 50, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insuman Implantable for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – if necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insuman Implantable, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insuman Infusat for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insuman Infusat, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insuman Rapid for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insuman Rapid, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients in a clinical trial for type 2 diabetes, who used a regimen of EXUBERA in combination with long- or intermediate-acting insulin, had similar changes in HbA1c compared with patients treated with subcutaneous insulin alone.
Bolniki z diabetesom tipa 2, ki so v kliničnem preskušanju uporabljali shemo z zdravilom EXUBERA v kombinaciji z dolgo- ali srednjedolgo-delujočim insulinom, so imeli podobne spremembe HbA1c kot bolniki, zdravljeni samo s subkutanim insulinom.
Patients in a severely immunocompromised state
Bolniki, ki so hudo imunsko oslabeli.
Patients in aHUS Study C08-002 A/B received Soliris for a minimum of 26 weeks.
Bolniki v študiji aHUS C08-002A/B so prejemali zdravilo Soliris najmanj 26 tednov.
Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of
V vseh zdravljenih skupinah so bolniki običajno prejemali 2 do 4 antihipertenzive (diuretike, zaviralce adrenergičnih receptorjev beta, zaviralce adrenergičnih receptorjev alfa), da so dosegli ciljni krvni tlak, ki je bil
Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was > 160 mmHg.
V vseh zdravljenih skupinah so bolniki običajno prejemali 2 do 4 antihipertenzive (diuretike, antagoniste adrenergičnih receptorjev beta, antagoniste adrenergičnih receptorjev alfa), da so dosegli ciljni krvni tlak, ki je bil ≤135/85 mmHg, ali znižanje krvnega tlaka za najmanj 10 mmHg, če je bil začetni krvni tlak >160 mmHg.
Patients in an autologous blood predonation programme
Bolniki, ki sodelujejo v programu avtolognega darovanja krvi
Patients in atrial fibrillation should receive 3 mg per kilogram body weight given as a 10-minute infusion into a vein.
Bolniki z atrijsko fibrilacijo morajo prejeti 3 mg zdravila na kilogram telesne mase v obliki 10-minutne infuzije v veno.
Patients in both arms received 1000mg of pulse intravenous (IV) methylprednisolone (or another equivalent-dose glucocorticoid) per day for 1 to 3 days, followed by oral prednisone (1 mg/kg/day, not exceeding 80 mg/day).
Bolniki v obeh terapevtskih skupinah so prejemali 1000 mg metilprednizolona (ali drugega glukokortikoida v enakovrednem odmerku) na dan pulzno intravensko (i.v.) od 1 do 3 dni, nato pa peroralni prednizon (1 mg/kg/dan in ne več kot 80 mg/dan).
Patients in both studies were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa).
Bolnike v obeh študijah so randomizirali v razmerju 1:1 na 150 mg ivakaftorja ali placebo skupaj z mastnim obrokom vsakih 12 ur za 48 tednov poleg njihovih predpisanih terapij CF (npr. tobramicin, dornaza alfa).
Patients in both study arms were permitted to switch to oral fluconazole after at least 10 days of intravenous therapy, provided that they were able to tolerate oral medication and were afebrile for at least 24 hours, and that the most recent blood cultures were negative for Candida species.
Bolniki v obeh krakih študije so lahko po vsaj 10 dneh intravenskega zdravljenja prešli na peroralni flukonazol; pogoji so bili, da so prenašali peroralno zdravilo, da so bili vsaj 24 ur afebrilni in da so bile najnovejše hemokulture negativne za Candida species.
Patients in both treatment arms were to receive 7 weeks of CRT following induction chemotherapy with a minimum interval of 3 weeks and no later than 8 weeks after start of the last cycle (day 22 to day 56 of last cycle).
Bolniki v obeh terapevtskih krakih so po indukcijski kemoterapiji dobili 7 tednov kemoradioterapije; najkrajši presledek je bil 3 tedne in ne več kot 8 tednov po začetku zadnjega kroga (22. do 56. dan zadnjega kroga).
Patients in both treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy.
Bolniki v obeh skupinah zdravljenja so v prvih 4 ciklih zdravljenja jemali 40 mg deksametazona enkrat na dan od 1. do 4. dne, od 9. do 12. dne in od 17. do 20. dne vsakega 28- dnevnega cikla.
Patients in clinical remission at week 6b
Bolniki v klinični remisiji v 6. tednub
Patients in clinical response (decrease in CDAI ≥ 70) at Week 4 were stratified and analysed separately from those not in clinical response at Week 4.
Bolnike s kliničnim odzivom (znižanje CDAI ≥ 70) 4. teden so stratificirali in analizirali ločeno od bolnikov brez kliničnega odziva 4. teden.
Patients in clinical response at week 6a
Bolniki s kliničnim odzivom v
Patients in clinical response at week 6a
Vzdrževanje odziva (bolniki s kliničnim odzivom do 54. tedna)e
Patients in controlled clinical trials in MS had serum samples collected 1, 3, and 12 months after each treatment course for determination of anti-alemtuzumab antibodies.
Bolnikom v kontroliranih kliničnih preskušanjih za MS so odvzeli vzorce seruma 1, 3 in 12 mesecev po vsakem ciklu zdravljenja za določitev protiteles proti alemtuzumabu.
Patients in each treatment group were maintained at their optimal dose for 6 months.
Bolniki v vseh skupinah so svoj optimalni odmerek prejemali 6 mesecev.
Patients in each treatment group were maintained for 4 months.
Bolniki v vseh skupinah so svoj optimalni odmerek prejemali 4 mesece.
Patients in response were followed for an additional 24 weeks off- treatment.
Bolnike, pri katerih je bil dosežen odziv, so spremljali še dodatnih 24 tednov po zdravljenju.
Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti- adalimumab antibodies during the 6 to 12 month period.
Pri bolnikih v študijah pri revmatoidnem artritisu I, II in III so v obdobju od 6 do 12 mesecev ob različnih časih večkrat določali protitelesa proti adalimumabu.
Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti- adalimumab antibodies during the 6 to 12 month period.
Pri bolnikih v študijah revmatoidnega artritisa I, II in III so v obdobju od 6 do 12 mesecev ob različnih časih večkrat določali protitelesa proti adalimumabu.
Patients in steroid-free remission for > = 90 daysa
Bolniki v remisiji brez steroidov za ≥ 90 dnia
Patients in steroid-free remission for >=90 daysa
Bolniki v remisiji brez steroidov ≥ 90 dnia
Patients in studies I – V had a mean Disease Activity Score (DAS28) of 6.5–6.8 at baseline.
Bolniki v študijah I–V so imeli povprečno izhodiščno oceno aktivnosti bolezni DAS28 (Disease Activity Score) od 6,5 do 6,8.
Patients in studies MCL-002 and MCL-001 that experienced Grade 1 and 2 TFR were treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms.
Bolnikom v študijah MCL- 002 in MCL-001, ki so imeli reakcijo izbruha tumorja 1. in 2. stopnje, so za obvladovanje simptomov dajali kortikosteroide, nesteroidna protivnetna zdravila (NSAIDs) in/ali narkotične analgetike.
Patients in the alirocumab 300 mg every 4 weeks treatment group received alternating placebo injections to maintain blinding in regard to injection frequency.
Bolniki v skupini, zdravljeni s 300 mg alirokumaba na 4 tedne, so izmenično prejemali injekcije placeba za ohranitev slepitve, kar zadeva pogostnost injekcij.
Patients in the BTDx and TDx groups respectively had a median age of 57 versus 56 years, 99% versus 98% patients were Caucasians, and 58% versus 54% were males.
V skupini BTDx oziroma TDx je bila mediana starost bolnikov 57 let oziroma 56 let, 99% oziroma 98% je bilo belcev, moških je bilo 58% oziroma 54%.
Patients in the BzmbR-CAP treatment arm received bortezomib (1.3 mg/m2; on days 1, 4, 8, 11, rest period days 12-21), rituximab 375 mg/m2 IV on day 1; cyclophosphamide 750 mg/m2 IV on day 1; doxorubicin 50 mg/m2 IV on day 1; and prednisone 100 mg/m2 orally on day 1 through day 5 of the 21 day bortezomib treatment cycle.
Bolniki v skupini BzmbR-CAP so prejeli bortezomib (1,3 mg/m2 na 1., 4., 8., in 11. dan, sledil je premor od 12. do 21. dne), 375 mg/m2 rituksimaba, 750 mg/m2 ciklofosfamida, 50 mg/m2 doksorubicina i.v. na 1. dan in 100 mg/m2 prednizona peroralno na 1. do 5. dan 21-dnevnega cikla zdravljenja z bortezomibom.
Patients in the chemotherapy arm were allowed to cross-over to the trametinib arm after independent confirmation of progression.
Bolnikom v skupini s kemoterapijo je bil dovoljen prehod v skupino s trametinibom, če je bilo neodvisno potrjeno napredovanje.
Patients in the combination arm received nivolumab 1 mg/kg over 60 minutes and ipilimumab 3 mg/kg over
Bolniki v skupini s kombiniranim zdravljenjem so pri prvih 4 odmerkih nivolumab prejemali v odmerku
Patients in the emtricitabine and tenofovir disoproxil fumarate group were given Truvada and efavirenz from week 96 to week 144.
Bolniki v skupini, ki je prejemala emtricitabin in dizoproksiltenofovirijev fumarat, so prejemali zdravilo Truvada in efavirenz od 96. do 144. tedna.
Patients in the Enbrel in combination with methotrexate therapy group had significantly higher ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and 52 weeks than patients in either of the single therapy groups (results shown in table below).
Pri bolnikih, ki so prejemali zdravilo Enbrel v kombinaciji z metotreksatom, so bili odzivi ACR 20, ACR 50 in ACR 70 ter izboljšanja na lestvicah ocene stopnje bolezni (DAS – Disease Activity Score) in HAQ tako po 24 kot po 52 tednih statistično pomembno večji kot pri bolnikih, ki so jih zdravili z enim samim zdravilom (izsledki so povzeti v spodnji preglednici).
Patients in the G+B arm who did not have disease progression (i.e. patients with a complete response (CR), partial response (PR) or stable disease (SD)) at the end of induction continued receiving Gazyvaro maintenance once every two months for two years or until disease progression (whichever occurred first).
Bolniki v skupini G + B, ki jim bolezen na koncu indukcije ni napredovala (tj. bolniki s popolnim odzivom (CR), delnim odzivom (PR) ali stabilno boleznijo (SD)), so še naprej prejemali vzdrževalno zdravljenje z zdravilom Gazyvaro enkrat na dva meseca v obdobju dveh let ali do napredovanja bolezni (kar od tega se je zgodilo prej).
Patients in the GLP-1 receptor agonist arm were to continue pre-trial GLP-1 receptor agonist treatment.
Bolniki v skupini z agonistom receptorjev GLP-1 so nadaljevali zdravljenje z agonistom receptorjev GLP-1 kot pred preskušanjem.
Patients in the immediate-release exenatide-treated group with an HbA1c 8.0% at the end of the BIO phase decreased their insulin glargine dose by at least 10%.
Bolniki, ki so prejemali eksenatid v obliki s takojšnjim sproščanjem in so imeli ob koncu OBI HbA1c ≤ 8,0 %, so zmanjšali odmerek insulina glargina za vsaj 10 %.
Patients in the laser control group could receive additional laser photocoagulation (called ‘rescue laser treatment’) beginning at week 12 with a minimum interval of 12 weeks.
Bolniki v kontrolni skupini z laserskim zdravljenjem so bili lahko dodatno zdravljeni z lasersko fotokoagulacijo (imenovano »rešilno lasersko zdravljenje«), ki se je začelo v 12. tednu, z najkrajšim intervalom 12 tednov.
Patients in the laser control group could receive additional laser photocoagulation (called ‘rescue laser treatment’) beginning at week 12, with a minimum interval of 12 weeks.
Bolniki v kontrolni skupini z laserskim zdravljenjem so bili lahko dodatno zdravljeni z lasersko fotokoagulacijo (imenovano »rešilno lasersko zdravljenje«), ki se je začelo v 12. tednu, z najkrajšim intervalom 12 tednov.
Patients in the liraglutide arm followed a fixed dose escalation scheme with a starting dose of 0.6 mg and a dose increase of 0.6 mg weekly until the maintenance dose of 1.8 mg was reached.
Bolniki v skupini z liraglutidom so sledili fiksni shemi stopnjevanja odmerka z začetnim odmerkom 0,6 mg in tedenskim povečanjem odmerka po 0,6 mg, dokler niso dosegli vzdrževalnega odmerka 1,8 mg.
Patients in the multicentre study had relapsed following 1-4 prior therapy regimens and 5 patients had relapsed following stem cell transplantation.
Pri bolnikih v multicentrični študiji je prišlo do relapsa po 1–4 predhodih krogih zdravljenja in pri 5 bolnikih je prišlo do relapsa po transplantaciji zarodnih celic.
patients in the perioperative liver transplantation period and in neonates up to 4 weeks of age.
pri bolnikih v perioperativen obdobju presaditve jeter in pri novorojenčkih, starih do 4 tedne.
Patients in the pivotal study BO21004/CLL11 were tested at multiple time-points for anti-therapeutic antibodies (ATA) to Gazyvaro.
Bolnike v ključni študiji BO21004/CLL11 so na več časovnih točkah testirali glede protiterapevtskih protiteles (anti-therapeutic antibodies – ATA) proti zdravilu Gazyvaro.
Patients in the pivotal trial CLEOPATRA were tested at multiple time-points for anti-therapeutic antibodies (ATA) to Perjeta.
Bolnikom v ključnem preskušanju CLEOPATRA so ob različnih časih večkrat določali antiterapevtska protitelesa (ATA – anti-therapeutic antibodies) proti zdravilu Perjeta.
Patients in the placebo/dexamethasone (placebo/dex) group took 1 placebo capsule on Days 1 to 28 of each 28-day cycle.
Bolniki v skupini, ki je prejemala placebo/deksametazon (placebo/deks), so jemali eno kapsulo s placebom od 1. do 28. dne vsakega 28- dnevnega cikla.
Patients in the Pom+LD-Dex arm were administered 4 mg pomalidomide orally on Days 1 to 21 of each 28-day cycle.
Bolnikom v skupini POM + NO-deks so dajali 4 mg pomalidomida peroralno od 1. do 21. dne vsakega 28-dnevnega cikla.
Patients in the Preotact treatment group had a 61 relative risk reduction of a new vertebral fracture at month 18 compared to the patients in the placebo group.
Bolnice, ki so prejemale zdravilo Preotact, so imele po 18 mesecih za 61% manjše relativno tveganje novega vretenčnega zloma v primerjavi z bolnicami, ki so prejemale placebo.
Patients in the Rd and Rd18 arms took lenalidomide 25 mg once daily on Days 1 to 21 of 28-day cycles according to protocol arm.
Bolniki v skupinah Rd and Rd18 so jemali lenalidomid 25 mg enkrat na dan od 1. do 21. dne 28- dnevnih ciklov v skladu s protokolom skupine.
Patients in the Rd and Rd18 arms took lenalidomide 25 mg once daily on Days 1 to 21 of 28-day cycles according to protocol arm.
Bolniki v skupinah Rd in Rd18 so jemali lenalidomid 25 mg enkrat na dan od 1. do 21. dne 28-dnevnih ciklov v skladu s protokolom skupine.
Patients in the second pivotal study had earlier participated in the Instanyl pharmacokinetic study or in the first pivotal study.
Bolniki v drugi ključni študiji so bodisi predhodno sodelovali v farmakokinetični študiji zdravila Instanyl ali v prvi ključni študiji.
Patients in the single centre study had relapsed following 1-6 prior therapy regimens and 2 patients had relapsed following stem cell transplantation.
Pri bolnikih v enocentrični študiji je prišlo do relapsa po 1–6 predhodih krogih zdravljenja in pri dveh bolnikih je prišlo do relapsa po transplantaciji zarodnih celic.
Patients in the study either continued with their current treatment or received Xultophy instead of the GLP-1 agonist.
Bolniki, ki jih je vključevala študija, so bodisi nadaljevali z dotedanjim zdravljenjem bodisi prejeli zdravilo Xultophy namesto antagonista GLP-1.
Patients in the study had high grade serous ovarian cancers, including fallopian tube or peritoneal.
Bolnice v tej študiji so imele slabo diferenciranega raka jajčnikov, vključno z rakom jajcevodov ali rakom peritoneja.
Patients in the study received Coagadex to treat any spontaneous bleeding that occurred during the treatment period or to prevent bleeding during surgery.
Bolniki v študiji so prejeli zdravilo Coagadex za zdravljenje kakršne koli spontane krvavitve v obdobju zdravljenja ali za preprečevanje krvavitve med operacijo.
Patients in the study received either Opsumit or placebo (a dummy treatment) in addition to other PAH treatments for an average of 2 years.
Bolniki v študiji so povprečno dve leti prejemali bodisi zdravilo Opsumit bodisi placebo (zdravilo brez zdravilne učinkovine) skupaj z drugimi zdravili za zdravljenje PAH.
Patients in the study were given Deltyba or placebo (a dummy treatment) for 2 months in addition to their other treatments.
Bolniki v študiji so poleg drugih oblik zdravljenja dva meseca prejemali zdravilo Deltyba ali placebo (zdravilo brez zdravilne učinkovine).
Patients in the sub-study (n=117) of the open-label extension of study SC-I received 125 mg of subcutaneous (SC) abatacept administered weekly via the pre-filled syringe for at least 4 months, and were then switched to receive 125 mg SC abatacept administered weekly via the pre-filled pen for 12 weeks.
Bolniki v podštudiji (n=117) odprtega podaljška študije SC-I so najmanj 4 mesece enkrat na teden prejemali 125 mg abatacepta subkutano (s.c.) v napolnjeni injekcijski brizgi, nato pa so za 12 tednov prešli na uporabo 125 mg abatacepta s.c. enkrat na teden v napolnjenem injekcijskem peresniku.
Patients in the Tresiba arm included 43 children aged 1–5 years, 70 children aged 6–11 years and 61 adolescents aged 12–17 years.
V skupino, ki je prejemala zdravilo Tresiba, je bilo vključenih 43 otrok, starih 1 – 5 let, 70 otrok, starih 6 – 11 let, in 61 mladostnikov, starih 12 – 17 let.
Patients in the Vitamin D3 2,800 group received ADROVANCE (70 mg/2,800 IU) (n=299) and patients in the Vitamin D3 5,600 group received ADROVANCE (70 mg/2,800 IU) plus an additional 2,800 IU vitamin D3 (n=309) once a week; additional vitamin D supplements were allowed.
Bolnice v skupini "Vitamin D3 2.800" so prejemale zdravilo ADROVANCE (70 mg/2.800 i.e.) (n = 299), bolnice v skupini "Vitamin D3 5.600" pa so prejemale zdravilo ADROVANCE (70 mg/2.800 i.e.) in dodatnih 2.800 i.e. vitamina D3
Patients in these studies had a diagnosis of AS for a median of 2.7 to 5.8 years.
Mediana diagnoze ankilozirajočega spondilitisa bolnikov v teh študijah je bila 2,7 do 5,8 let.
Patients in these studies had a diagnosis of PsA for a median of 3.9 to 5.3 years.
Mediana diagnoze psoriatičnega artritisa bolnikov v obeh študijah je bila 3,9 do 5,3 let.
Patients in these studies had a diagnosis of PsA for at least 6 months.
Bolniki v teh študijah so imeli diagnozo PsA vsaj 6 mesecev.
Patients in this study (n=1,927) received open-label CHAMPIX 1 mg twice daily for 12 weeks.
Bolniki (n = 1.927) so v tej študiji, ki je bila prvih 12 tednov odprta, v tem obdobju dobivali zdravilo CHAMPIX v odmerku 1 mg dvakrat na dan.
Patients in unstable hemodynamic conditions,
Bolniki z nestabilnimi hemodinamskimi stanji.
Patients in whom the blood supply to the extremity distal to the tumour is suspected to be highly dependent on tumour associated blood vessels.
Bolniki, pri katerih obstaja sum, da je dotok krvi v okončino, distalno od tumorja, zelo odvisen od krvnih žil, ki so povezane s tumorjem.
Patients in whom the first treatment course led to complete clearance were seen at 26 and 44 weeks and randomised to a second treatment course if they had a recurrence in the field.
Bolnike, pri katerih so s prvim ciklom zdravljenja dosegli popolno ozdravitev, so ponovno pregledali v 26. in 44. tednu ter jih randomizirali na dodaten cikel zdravljenja, če se je na zdravljenem predelu bolezen ponovila.
Patients in whom the first treatment course led to complete clearance were seen at 26 and 44 weeks and randomised to a second treatment course if they had a recurrence in the field.
Bolnike, pri katerih so s prvim krogom zdravljenja dosegli popolno ozdravitev, so ponovno pregledali v 26. in 44. tednu ter jih randomizirali na dodaten krog zdravljenja, če se je na zdravljenem predelu bolezen ponovila.
Patients included in analysis
Število bolnikov, vključenih v analizo
Patients included in safety analysis
Bolniki, vključeni v analizo o varnosti
Patients included in the trial had a total disease duration of at least 6 months and active disease but were not experiencing an acute flare requiring corticosteroid doses of more than 0.5 mg/kg prednisone equivalent.
Pri bolnikih, vključenih v študijo, je bolezen trajala vsaj 6 mesecev, bila je aktivna, vendar ob vključitvi bolniki niso doživljali nenadnega poslabšanja bolezni, za katerega bi potrebovali odmerke kortikosteroida, večje od ekvivalenta 0,5 mg/kg prednizona.
Patients infected with a pre-XDR-TB
bolniki s pre-XDR-TB